(MENAFN- Trend News Agency) Head of Pasteur Institute of Iran declared Wednesday the start of third phase of double-blind clinical trial of Iranian-Cuban COVID-19 vaccine in future weeks, Trend reports citing IRNA .
The joint vaccine is produced in both countries, Ali-Reza Biglari told reporters at a virtual meeting.
First, the vaccine is transported from Cuba to Iran, second Iran tests its quality, then it will be presented to people as the time is possibly slated for June, Biglari said.
Then, two million doses of vaccine will be presented monthly, he added.
Most importantly, as he noted, the joint Iran-Cuba vaccine is reliable in terms of trade.
About the PII, the official said it is a century-old brand, so reliability of a vaccine is so important to the institute and it does not sacrifice its good record for a mistake.
Further, he noted he has a good news about which will be talked in future.
Biglari went on to say that the pandemic advanced Iran's vaccine production industry by 20 years.
About why PII selected the Cuban vaccine, the official said transportation of its technology was easier than the other ones, its side effects were fewer than others and its technology is much more like the one Iran is producing.
Biglari underlined that Iran supervising and witnessing each step being taken from the outset to manufacture the Iranian-Cuban vaccine.
MENAFN03022021000187011040ID1101542593
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.